S
Saraswathy V. Nochur
Researcher at Alnylam Pharmaceuticals
Publications - 14
Citations - 4149
Saraswathy V. Nochur is an academic researcher from Alnylam Pharmaceuticals. The author has contributed to research in topics: Transthyretin & Tafamidis. The author has an hindex of 9, co-authored 14 publications receiving 3210 citations.
Papers
More filters
Journal ArticleDOI
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
David Adams,Alejandra González-Duarte,William O'Riordan,Chih-Chao Yang,Mitsuharu Ueda,Arnt V. Kristen,Ivailo Tournev,Hartmut Schmidt,Teresa Coelho,John L. Berk,Kon Ping Lin,Giuseppe Vita,Shahram Attarian,Violaine Planté-Bordeneuve,Michelle M. Mezei,Josep M. Campistol,Juan Buades,Thomas H. Brannagan,Byoung Joon Kim,Jeeyoung Oh,Yesim Parman,Yoshiki Sekijima,Philip N. Hawkins,Scott D. Solomon,Michael Polydefkis,Peter J. Dyck,Pritesh Gandhi,Sunita Goyal,Jihong Chen,Andrew Strahs,Saraswathy V. Nochur,Marianne T. Sweetser,Pushkal Garg,Pushkal Garg,Akshay Vaishnaw,Akshay Vaishnaw,Jared Gollob,Ole B. Suhr +37 more
TL;DR: Patisiran improved multiple clinical manifestations of hereditary transthyretin amyloidosis with polyneuropathy and showed an effect on gait speed and modified BMI.
Journal ArticleDOI
Safety and efficacy of RNAi therapy for transthyretin amyloidosis
Teresa Coelho,David H. Adams,Ana Martins da Silva,Pierre Lozeron,Philip N. Hawkins,Timothy Mant,Javier Perez,Joseph Chiesa,Steve Warrington,Elizabeth Tranter,Malathy Munisamy,Rick Falzone,Jamie Harrop,Jeffrey Cehelsky,Brian Bettencourt,Mary Geissler,James Butler,Alfica Sehgal,Rachel Meyers,Qingmin Chen,Todd Borland,Renta Hutabarat,Valerie A. Clausen,Rene Alvarez,Kevin Fitzgerald,Christina Gamba-Vitalo,Saraswathy V. Nochur,Akshay Vaishnaw,Dinah W.Y. Sah,Jared Gollob,Ole B. Suhr +30 more
TL;DR: A therapeutic approach mediated by RNA interference (RNAi) could reduce the production of transthyretin in peripheral nerves and the heart as mentioned in this paper, which is caused by the deposition of hepatocyte-derived tranthymretin amyloid in peripheral nerve and heart.
Journal ArticleDOI
First-in-Humans Trial of an RNA Interference Therapeutic Targeting VEGF and KSP in Cancer Patients with Liver Involvement
Josep Tabernero,Geoffrey I. Shapiro,Patricia LoRusso,Andrés Cervantes,Gary K. Schwartz,Glen J. Weiss,Luis Paz-Ares,Daniel C. Cho,Jeffrey R. Infante,Maria Alsina,Mrinal M. Gounder,Rick Falzone,Jamie Harrop,Amy C. Seila White,Ivanka Toudjarska,David Bumcrot,Rachel Meyers,Gregory Hinkle,Nenad Svrzikapa,Renta Hutabarat,Valerie A. Clausen,Jeffrey Cehelsky,Saraswathy V. Nochur,Christina Gamba-Vitalo,Akshay Vaishnaw,Dinah W.Y. Sah,Jared Gollob,Howard A. Burris +27 more
TL;DR: Safety, pharmacokinetics, RNAi mechanism of action, and clinical activity with a novel LNP-formulated RNAi therapeutic in patients with cancer are shown, providing proof-of-concept for RNAi therapeutics in humans and the basis for further development in cancer.
Journal ArticleDOI
Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial
Kevin Fitzgerald,Maria Frank-Kamenetsky,Svetlana Shulga-Morskaya,Abigail Liebow,Brian Bettencourt,Jessica E. Sutherland,Renta Hutabarat,Valerie A. Clausen,Verena Karsten,Jeffrey Cehelsky,Saraswathy V. Nochur,Victor Kotelianski,Jay D. Horton,Timothy Mant,Joseph Chiesa,JM Ritter,Malathy Munisamy,Akshay Vaishnaw,Jared Gollob,Amy Simon +19 more
TL;DR: The results suggest that inhibition of PCSK9 synthesis by RNA interference (RNAi) provides a potentially safe mechanism to reduce LDL cholesterol concentration in healthy individuals with raised cholesterol.
Journal ArticleDOI
Viral Load Drives Disease in Humans Experimentally Infected with Respiratory Syncytial Virus
John P. DeVincenzo,Tom Wilkinson,Akshay Vaishnaw,Jeff Cehelsky,Rachel Meyers,Saraswathy V. Nochur,Lisa Harrison,Patricia Meeking,Alex Mann,Elizabeth Moane,John S. Oxford,Rajat Pareek,Ryves Moore,Ed Walsh,Robert Studholme,Preston Dorsett,Rene Alvarez,Rob Lambkin-Williams +17 more
TL;DR: Viral load appears to drive disease manifestations in humans with RSV infection, and the observed parallel viral and disease kinetics support a potential clinical benefit of RSV antivirals and facilitates the development of future RSV therapeutics.